Ignite Creation Date:
2025-12-26 @ 12:16 PM
Ignite Modification Date:
2025-12-29 @ 4:44 PM
Study NCT ID:
NCT02021500
Status:
COMPLETED
Last Update Posted:
2019-11-01
First Post:
2013-12-20
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study to Collect Survival Data on Patients Previously Enrolled in Abraxane Pancreatic Cancer Study CA046.
Sponsor:
Celgene
Organization:
Study Overview
Official Title:
MPACT Extension Study: Multicenter, Survival Data Collection in Subjects Previously Enrolled in Protocol CA046
Status:
COMPLETED
Status Verified Date:
2019-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A study to collect survival data on patients previously enrolled in Abraxane pancreatic cancer study CA046.
Detailed Description:
A study to collect survival status of CA046 subjects who were know to be alive at the last report of vital status for CA046 - approximate timeframe - end of March, 2013. Once consent is given, on a quarterly basis, information on status will be collected to include:
* Vital Status
* Date of disease progression
* Subsequent anticancer therapy for pancreatic adenocarcinoma
* Vital Status
* Date of disease progression
* Subsequent anticancer therapy for pancreatic adenocarcinoma
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: